CD19 and chronic kidney disease: The results of CD19(+)CD5(−) B cells were similar, higher levels of CD19(+)CD5(−) B cells (> 0.05 × 109 /L) exhibited better survival in the total cohort (57.57 ± 7.16 vs. 83.86 ± 3.26 months, P = 0.001, Fig. 3G) and CKD group (49.18 ± 7.98 vs. 73.73 ± 4.16 months, P = 0.007, Fig. 3H).